Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Monopar Therapeutics changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 13 | 10 | −3 |
| Shares | 208.0K | 199.1K | −8.91K (−4.3%) |
| Value | $470.6K | $314.0K | −$156.6K (−33.3%) |
New holders (2)
Institutions that held Monopar Therapeutics at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 10,584 | $16.0K | 0.00% |
| Paragon Wealth Strategies, LLC | 58 | $0 | 0.00% |
Sold out (5)
Institutions that held Monopar Therapeutics at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Royal Bank of Canada | 4,116 | $9.00K |
| BlackRock Inc. | 2,327 | $5.00K |
| American Portfolios Advisors | 700 | $1.61K |
| FMR LLC | 10 | $0 |
| Captrust Financial Advisors | 170 | $0 |